Based on these findings, RBN-2397 is currently being tested in clinical trials in combination with pembrolizumab, an anti–PD-1 immune checkpoint inhibitor (ICI), in patients with squamous cell carcinoma of the lung, aiming to restore response to PD-1/programmed cell death ligand 1 (PD-L1) inhibitors (NCT05127590). Here, CD274 is linked to squamous cell lung carcinoma.